These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8805993)

  • 1. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.
    Rizzoli R; Forni M; Schaad MA; Slosman DO; Sappino AP; Garcia J; Bonjour JP
    Bone; 1996 Jun; 18(6):531-7. PubMed ID: 8805993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of oral clodronate on bone mass, bone turnover and subsequent metastases in women with primary breast cancer.
    McCloskey E; Paterson A; Kanis J; Tähtelä R; Powles T
    Eur J Cancer; 2010 Feb; 46(3):558-65. PubMed ID: 20031392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of different treatment modalities for postmenopausal patients with osteopenia: hormone replacement therapy, calcitonin and clodronate.
    Tiraş MB; Noyan V; Yildiz A; Biberoğlu K
    Climacteric; 2000 Jun; 3(2):92-101. PubMed ID: 11910657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clodronate is effective in preventing corticosteroid-induced bone loss among asthmatic patients.
    Herrala J; Puolijoki H; Liippo K; Raitio M; Impivaara O; Tala E; Nieminen MM
    Bone; 1998 May; 22(5):577-82. PubMed ID: 9600795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
    Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
    Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
    Powles TJ; McCloskey E; Paterson AH; Ashley S; Tidy VA; Nevantaus A; Rosenqvist K; Kanis J
    J Natl Cancer Inst; 1998 May; 90(9):704-8. PubMed ID: 9586668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women.
    Gnudi S; Lisi L; Fini M; Malavolta N
    Int J Tissue React; 2001; 23(1):33-7. PubMed ID: 11392061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss.
    Giannini S; D'Angelo A; Sartori L; Passeri G; Dalle Carbonare L; Crepaldi G
    Obstet Gynecol; 1996 Sep; 88(3):431-6. PubMed ID: 8752254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass.
    Filipponi P; Cristallini S; Policani G; Schifini MF; Casciari C; Garinei P
    Bone; 2000 Mar; 26(3):269-74. PubMed ID: 10710000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clodronate decreases the frequency of skeletal metastases in women with breast cancer.
    Kanis JA; Powles T; Paterson AH; McCloskey EV; Ashley S
    Bone; 1996 Dec; 19(6):663-7. PubMed ID: 8968035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intramuscular clodronate in nonresponders to oral alendronate therapy for osteoporosis.
    del Puente A; Scognamiglio A; Itto E; Ferrara G; Oriente P
    J Rheumatol; 2000 Aug; 27(8):1980-3. PubMed ID: 10955341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up.
    Tuppurainen M; Härmä K; Komulainen M; Kiviniemi V; Kröger H; Honkanen R; Alhava E; Jurvelin J; Saarikoski S
    Maturitas; 2010 Aug; 66(4):423-30. PubMed ID: 20547017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effectiveness of cyclic and continuous oral clodronate therapy on bone density and markers in osteopenic postmenopausal women.
    Tsai KS; Hsu SH; Yang RS; Cheng WC; Chieng PU
    Calcif Tissue Int; 1999 May; 64(5):384-8. PubMed ID: 10203414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases].
    Tubiana-Hulin M; Beuzeboc P; Mauriac L; Barbet N; Frenay M; Monnier A; Pion JM; Switsers O; Misset JL; Assadourian S; Bessa E
    Bull Cancer; 2001 Jul; 88(7):701-7. PubMed ID: 11495824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Short-term intravenous bisphosphonates in prevention of postmenopausal bone loss.
    Heikkinen JE; Selander KS; Laitinen K; Arnala I; Väänänen HK
    J Bone Miner Res; 1997 Jan; 12(1):103-10. PubMed ID: 9240732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy.
    Filipponi P; Pedetti M; Fedeli L; Cini L; Palumbo R; Boldrini S; Massoni C; Cristallini S
    J Bone Miner Res; 1995 May; 10(5):697-703. PubMed ID: 7639104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.